ProQR to Participate in 8th Annual Evercore Healthcare Conference

About this update from Proqr Therapeutics N.v.

[{"type":"image","alt":"ProQR Therapeutics N.V.","displaySize":"","headline":null,"caption":"ProQR Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4HUbXKqR88bsVsQR5pPVmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3","width":150,"height":150}},"lazy":false},{"type":"text","content":"LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET.","length":443,"tagName":"p"},{"type":"text","content":"Webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under "Events". Archived webcasts will be available for approximately 30 days following the presentation date.","length":236,"tagName":"p"},{"type":"text","content":"About Axiomer™","length":14,"tagName":"p"},{"type":"text","content":"ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.","length":791,"tagName":"p"},{"type":"text","content":"About ProQR","length":11,"tagName":"p"},{"type":"text","content":"ProQR Therapeutics is dedicated to changing lives through t...

More updates from Proqr Therapeutics N.v.